



Rapid 
Quality, Simplified

Product Catalogue

Table of Contents

| | |
|---------------------------------------|----|
| What is Point-of-Care Testing? | 3 |
| RapidQ Model | 4 |
| Our Features | 5 |
| EDCNet | 6 |
| Ready-To-Order Products | 7 |
| HBV | 8 |
| HCV | 9 |
| HIV | 11 |
| SARS-CoV-2 | 12 |
| Serology Multi-marker | 13 |
| C. trachomatis, N. gonorrhoeae | 14 |
| Syphilis | 15 |
| Tuberculosis | 16 |
| In-Development | 17 |
| HPV & Group A Strep | 18 |
| Contact us | 19 |



RapidQ ensures reliable results, **anytime, anywhere**

What is Point-of-Care Testing?

Point-of-Care Testing (PoCT) enables diagnostic testing close to the patient, providing immediate results that directly impact clinical decisions. This rapid result availability is crucial in settings where follow-up care is difficult due to geographic, social, economic, or environmental challenges.

PoCT's versatility is evident in its use of rapid diagnostic tests (RDTs) and portable molecular testing (NATs) for infectious diseases like SARS-CoV-2. These technologies are easy to use and don't require specialised laboratory equipment, making PoCT ideal for non-traditional settings such as schools, airports, and workplaces.

However, PoCT, like all diagnostic testing, is regulated and requires regular performance reviews. These checks are often harder to conduct in non-laboratory environments, especially when tests are performed by non-laboratory professionals. Testing failures can result in poor patient outcomes, resource waste, inaccurate epidemiological data, and the spread of infections, underscoring the need for robust quality assurance (QA) programs.

Current QA programs are tailored for well-resourced laboratories and are often cost-prohibitive for resource-limited settings. To address this gap, **NRL has developed a specialised QA model for infectious disease PoCT, designed specifically for these environments.**



RapidQ Model

The RapidQ program is comprised of two key components:

Competency Panels (CP):

Competency Panels consist of known positive and negative samples. The positive sample exhibits moderate reactivity across most PoCT methods. These panels are tested periodically to assess assay performance and user competence.

External Quality Assessment Panels (EQA):

EQA panels follow the same structure as NRL traditional programs, consisting of four vials with varying reactivity, unknown to the operator. The operator tests and reports results as if from real patient samples, with immediate feedback provided upon submission.

RapidQ Program Design:

The RapidQ program supports PoCT sites in meeting quality standards. Sites should regularly participate in competency assessments and use EQA to confirm the detection of various analytes. While participation frequency is flexible, NRL recommends specific intervals for each site, as outlined *below*.

| Minimum quality testing for sites | Optimal quality testing for sites |
|------------------------------------|--|
| CP testing once per month | CP testing once per week |
| EQAS testing twice per year | EQAS testing three times per year |

RapidQ Programs are designed for analyte specific testing. Please contact NRL to determine availability in your region or if you would like to partner with us to develop other PoCT QA programs.



Our Features

RapidQ Management

The RapidQ model is delivered through Implementing Partners, not directly to individual test sites. NRL partners with organisations like the World Health Organization (WHO), ministries of health, IVD manufacturers, and major procurement bodies (e.g., the Global Fund, the Clinton Foundation, FIND) to manage networks of test sites. Regulatory authorities reviewing IVD performance may also act as Implementation Partners.

Logistics

Implementing Partners order RapidQ panels for 6-12 months to supply their test site networks. The panels are shipped ambient, requiring no UN3373 compliance. Local regulations must be followed, though importation permits may not be necessary. The panels are stored at a centralised warehouse under NRL's specified conditions before being distributed to test sites, where they can be stored at 2-8°C or room temperature.

Samples

The RapidQ competency and EQAS panels contain non-infectious, well-characterised clinical or biological materials, such as whole viruses or bacteria. These samples are validated for most PoCT devices and are not extracted nucleic acids or recombinant materials.

Storage

RapidQ panel samples are stable for **24 months** when frozen (*select panels*), **6-8 months** at 2-8°C, and **3 months** at room temperature.

Software

NRL has developed an informatics system, built on EDCNet™, for result entry and data analysis via QR code mobile technology. This system supports PoCT sites that lack regular computer-based internet access, as most individuals have smartphones. This innovative approach facilitates participation in QA without time and software restrictions.

Result Analysis

All data are stored in a central database and analysed periodically. Any unusual variations in test performance are reported to the test site, Implementing Partner, and IVD manufacturer. Critical issues may be escalated to the WHO and regulatory authorities



EDCNet™


First developed by NRL in 2001, EDCNet™ has been a cornerstone of our international quality control programs for over two decades. As a global leader in infectious disease testing monitoring, NRL has consistently advanced quality control practices beyond traditional methods. Now, this expertise is powering RapidQ, with EDCNet™ enhanced to support both qualitative and quantitative data monitoring.

What is EDCNet?

- A virtual, cloud-based database-accessible from anywhere with internet access.
- No software installation required- just enrol and log in.
- Fully GDPR compliant (EU 2016/679).
- Six languages - English, French, German, Italian, Spanish and Polish

How it Works


1. **Enrolment:** Each test site joins EDCNet™ and is issued unique user logins.
2. **Registration:** Sites register their test kits and instrumentation in the system.
3. **Panel Access:** When Competency or EQAS panels are received, users simply scan the QR code on the box.
4. **Auto-Fill:** The system pre-fills key fields (e.g., test kits, panel names, instrument details).



5. **Data Entry:** Users select the sample, reagent lot number, operator name, and testing date.
6. **Instant Feedback:** Once submitted, the results are analysed and immediate performance feedback is provided.

What Happens to the Data?

- All results are securely stored in a central database.
- Data are analysed by NRL staff in real time.
- Unusual or unexpected results are investigated, ensuring accuracy and reliability.
- Reports are generated and shared with the test site, Implementing Partner, and/or IVD manufacturer, depending on the context.





READY-TO-ORDER PRODUCTS

1. HBV SEROLOGY RDT COMPETENCY

| SHIPPING CONDITION: Ambient ANALYSIS: Qualitative SAMPLE TYPE: Synthetic Whole Blood-like Sample | | |
|--|--|---|
| PROGRAM CODES | FORMAT | COMPATIBILITY |
| SC11058 SC11052 SC11053 | 2 vial; 0.5mL each (1 x POS, 1 x NEG) 2 vial; 0.5mL each (2 x NEG) 2 vial; 0.5mL each (2 x POS) | HBV rapid diagnostic tests (RDTs) testing serum, plasma or capillary whole blood. |
| HBsAg | | |
| DESCRIPTION | | |
| The positive vial consists of human whole blood-like sample known to be positive for HBsAg at a known reactivity. The negative sample is uninfected human whole blood-like sample. | | |

2. HBV SEROLOGY RDT POC EQA

| SHIPPING CONDITION: Ambient ANALYSIS: Qualitative SAMPLE TYPE: Synthetic Whole Blood-like Sample | | |
|--|---------------------------|---|
| PROGRAM CODES | FORMAT | COMPATIBILITY |
| HBSR4 | 4 vial; 0.5mL each | Rapid diagnostic tests (RDTs) testing serum, plasma or capillary whole blood. |
| HBsAg | | |
| DESCRIPTION | | |
| Each vial consists of human whole blood-like sample, positive or negative for HBsAg of various genotypes and concentrations. | | |

3. HBV DRIED PLASMA MOLECULAR COMPETENCY

| SHIPPING CONDITION: Ambient ANALYSIS: Qualitative & Quantitative SAMPLE TYPE: Dried Human Plasma Matrix | | |
|--|--|---|
| PROGRAM CODES | FORMAT | COMPATIBILITY |
| MC11058 MC11052 MC11053 | 4 vial: 2 vials dry (1 x POS, 1 x NEG), 2 vials 1.2mL (PBS) 4 vial: 2 vials dry (2 x NEG), 2 vials 1.2mL each (PBS) 4 vial: 2 vials dry (2 x POS), 2 vials 1.2mL each (PBS) | HBV molecular tests that use serum or plasma. |
| HBV DNA | | |
| DESCRIPTION | | |
| The positive vial consists of dried human plasma known to be infected with HBV DNA at a specified concentration. The negative sample is dried uninfected human plasma. The reconstitution buffer is phosphate buffered saline (PBS). | | |

4. HBV DRIED PLASMA MOLECULAR POC EQA

| SHIPPING CONDITION: Ambient ANALYSIS: Qualitative & Quantitative SAMPLE TYPE: Dried Human Plasma Matrix | | |
|--|--|---|
| PROGRAM CODE | FORMAT | COMPATIBILITY |
| DPBR4 | 8 vial: 4 vials dry, 4 vials 1.2mL each (PBS) | HBV molecular tests that use serum or plasma. |
| HBV DNA | | |
| DESCRIPTION | | |
| Each vial consists of dried human plasma either uninfected or infected with HBV DNA of various genotypes and concentrations. The reconstitution buffer is phosphate buffered saline (PBS). | | |

1. HCV SEROLOGY RDT COMPETENCY

| SHIPPING CONDITION: Ambient ANALYSIS: Qualitative SAMPLE TYPE: Synthetic Whole Blood-like Sample | | |
|---|--|---|
| PROGRAM CODES | FORMAT | COMPATIBILITY |
| SC11028 SC11022 SC11023 | 2 vial; 0.5mL each (1 x POS, 1 x NEG) 2 vial; 0.5mL each (2 x NEG) 2 vial; 0.5mL each (2 x POS) | HCV rapid diagnostic tests (RDTs) testing serum, plasma or capillary whole blood. |
| anti-HCV | | |
| DESCRIPTION | | |
| The positive vial consists of human whole blood-like sample known to be positive for anti-HCV at a known reactivity. The negative sample is uninfected human whole blood-like sample. | | |

2. HCV SEROLOGY RDT POC EQA

| SHIPPING CONDITION: Ambient ANALYSIS: Qualitative SAMPLE TYPE: Synthetic Whole Blood-like Sample | | |
|---|---------------------------|---|
| PROGRAM CODE | FORMAT | COMPATIBILITY |
| HCSR4 | 4 vial; 0.5mL each | HCV rapid diagnostic tests (RDTs) testing serum, plasma or capillary whole blood. |
| anti-HCV | | |
| DESCRIPTION | | |
| Each vial consists of human whole blood-like sample, positive or negative for anti-HCV of various genotypes and concentrations. | | |

3. HCV WHOLE BLOOD MOLECULAR COMPETENCY

| SHIPPING CONDITION: Ambient ANALYSIS: Qualitative & Quantitative SAMPLE TYPE: Dried Human Whole-Blood Matrix | | |
|--|---|---|
| PROGRAM CODES | FORMAT | COMPATIBILITY |
| MC20028 MC20022 MC20023 | 4 vial: 2 vials dry (1 x POS, 1 x NEG), 2 vials 0.25mL (PBS) 4 vial: 2 vials dry (2 x NEG), 2 vials 0.25mL each (PBS) 4 vial: 2 vials dry (2 x POS), 2 vials 0.25mL each (PBS) | HCV molecular tests that use fingerstick whole blood. |
| HCV RNA | | |
| DESCRIPTION | | |
| The positive vial consists of dried human whole blood known to be infected with HCV RNA at a specified concentration. The negative sample is dried uninfected human whole blood. The reconstitution buffer is phosphate buffered saline (PBS). | | |

4. HCV WHOLE BLOOD MOLECULAR POC EQA

| SHIPPING CONDITION: Ambient ANALYSIS: Qualitative & Quantitative SAMPLE TYPE: Dried Human Whole-Blood Matrix | | |
|---|--|---|
| PROGRAM CODES | FORMAT | COMPATIBILITY |
| DBCR4 | 8 vial: 4 vials dry, 4 vials 0.25mL (PBS) | HCV molecular tests that use fingerstick whole blood. |
| HCV RNA | | |
| DESCRIPTION | | |
| Each vial consists of dried human whole blood either uninfected or infected with HCV RNA of various genotypes and concentrations. The reconstitution buffer is phosphate buffered saline (PBS). | | |

5. HCV DRIED PLASMA MOLECULAR COMPETENCY

| SHIPPING CONDITION: Ambient | | | ANALYSIS: Qualitative & Quantitative | | | SAMPLE TYPE: Dried Human Plasma Matrix | | |
|--|--|---|---|--|---|---|--|--|
| PROGRAM CODES | | FORMAT | | | COMPATIBILITY | | | |
| MC11028 | | 4 vial: 2 vials dry (1 x POS, 1 x NEG), 2 vials 1.2mL (PBS) | | | HCV molecular tests that use serum or plasma. | | | |
| MC11022 | | 4 vial: 2 vials dry (2 x NEG), 2 vials 1.2mL each (PBS) | | | | | | |
| MC11023 | | 4 vial: 2 vials dry (2 x POS), 2 vials 1.2mL each (PBS) | | | | | | |
| HCV RNA | | | | | | | | |
| DESCRIPTION | | | | | | | | |
| The positive vial consists of dried human plasma known to be infected with HCV RNA at a specified concentration. The negative sample is dried uninfected human plasma. The reconstitution buffer is phosphate buffered saline (PBS). | | | | | | | | |

6. HCV DRIED PLASMA MOLECULAR POC EQA

| SHIPPING CONDITION: Ambient | | | ANALYSIS: Qualitative & Quantitative | | | SAMPLE TYPE: Dried Human Plasma Matrix | | | | | | |
|--|--|---|---|--|---|---|--|--|--|--|--|--|
| PROGRAM CODES | | FORMAT | | | COMPATIBILITY | | | | | | | |
| DPCR4 | | 8 vial: 4 vials dry, 4 vials 1.2mL each (PBS) | | | HCV molecular tests that use serum or plasma. | | | | | | | |
| HCV RNA | | | | | | | | | | | | |
| DESCRIPTION | | | | | | | | | | | | |
| Each vial consists of dried human plasma either uninfected or infected with HCV RNA of various genotypes and concentrations. The reconstitution buffer is phosphate buffered saline (PBS). | | | | | | | | | | | | |

1. HIV SEROLOGY RDT COMPETENCY

| SHIPPING CONDITION: Ambient ANALYSIS: Qualitative SAMPLE TYPE: Synthetic Whole Blood-like sample | | |
|---|---|---|
| PROGRAM CODES | FORMAT | COMPATIBILITY |
| SC11038 SC11032 SC11033 | 2 vial; 0.5mL each (1 x POS, 1 x NEG) 2 vial; 0.5mL each (2 x NEG) 2 vial; 0.5mL each (2 x POS) | HIV rapid diagnostic tests (RDTs) testing serum, plasma or capillary whole blood. |
| anti-HIV | | |
| DESCRIPTION | | |
| The positive vial consists of a human whole blood-like sample known to be positive for anti-HIV at a known reactivity. The negative sample is uninfected human whole blood-like sample. | | |

2. HIV SEROLOGY RDT POC EQA

| SHIPPING CONDITION: Ambient ANALYSIS: Qualitative SAMPLE TYPE: Synthetic Whole Blood-like Sample | | |
|---|--------------------|---|
| PROGRAM CODES | FORMAT | COMPATIBILITY |
| HISR4 | 4 vial; 0.5mL each | HIV rapid diagnostic tests (RDTs) testing serum, plasma or capillary whole blood. |
| anti-HIV HIV p24 Ag | | |
| DESCRIPTION | | |
| Each vial consists of whole blood-like sample, positive or negative for anti-HIV and/or HIV p24 Ag of various genotypes and concentrations. | | |

3. HIV DRIED PLASMA MOLECULAR COMPETENCY

| SHIPPING CONDITION: Ambient ANALYSIS: Qualitative & Quantitative SAMPLE TYPE: Dried Human Plasma Matrix | | |
|--|---|--|
| PROGRAM CODES | FORMAT | COMPATIBILITY |
| MC11038 MC11032 MC11033 | 4 vial: 2 vials dry (1 x POS, 1 x NEG), 2 vials 1.2mL (PBS) 4 vial: 2 vials dry (2 x NEG), 2 vials 1.2mL each (PBS) 4 vial: 2 vials dry (2 x POS), 2 vials 1.2mL each (PBS) | HIV molecular tests that use serum, plasma and assays used in molecular early infection diagnostics. |
| HIV RNA HIV Proviral DNA | | |
| DESCRIPTION | | |
| The positive vial consists of dried human plasma known to be infected with HIV RNA and/or HIV Proviral DNA at a specified concentration. The negative sample is dried uninfected human plasma. The reconstitution buffer is phosphate buffered saline (PBS). | | |

4. HIV DRIED PLASMA MOLECULAR POC EQA

| SHIPPING CONDITION: Ambient ANALYSIS: Qualitative & Quantitative SAMPLE TYPE: Dried Human Plasma Matrix | | |
|---|---|--|
| PROGRAM CODES | FORMAT | COMPATIBILITY |
| DPIR4 | 8 vial: 4 vials dry, 4 vials 1.2mL each (PBS) | HIV molecular tests that use serum, plasma and assays used in molecular early infection diagnostics. |
| HIV RNA HIV Proviral DNA | | |
| DESCRIPTION | | |
| Each vial consists of dried human plasma either uninfected or infected with HIV RNA and/or HIV proviral DNA of various genotypes or concentrations. The reconstitution buffer is phosphate buffered saline (PBS). | | |

1. SARS-COV-2 ANTIGEN RDT COMPETENCY

| SHIPPING CONDITION: Ambient ANALYSIS: Qualitative SAMPLE TYPE: Clinical Liquid Sample | | |
|---|---|--|
| PROGRAM CODES | FORMAT | COMPATIBILITY |
| SC18088 SC18082 SC18083 | 2 vial; 0.05mL each (1 x POS, 1 x NEG) 2 vial; 0.05mL each (2 x NEG) 2 vial; 0.05mL each (2 x POS) | Most COVID-19 Ag Rapid Diagnostic Tests (RDTs) (Contact NRL for more details). |
| SARS-CoV-2 Antigen | | |
| DESCRIPTION | | |
| The positive vial consists of inactivated SARS-CoV-2 virus suspended in a transport medium. The negative vial contains uninoculated transport medium. | | |

2. SARS-COV-2 ANTIGEN RDT POC EQA

| SHIPPING CONDITION: Ambient ANALYSIS: Qualitative SAMPLE TYPE: Clinical Liquid Sample | | |
|--|-----------------------|--|
| PROGRAM CODES | FORMAT | COMPATIBILITY |
| SCVR4 | 4 vial; 0.05mL | Most COVID-19 Ag Rapid Diagnostic Tests (RDTs) (Contact NRL for more details). |
| SARS-CoV-2 Antigen | | |
| DESCRIPTION | | |
| Each vial contains either uninoculated transport medium or inactivated SARS-CoV-2 virus variants of concern at different concentrations. | | |

1. MULTI-MARKER SEROLOGY RDT COMPETENCY

| SHIPPING CONDITION: Ambient ANALYSIS: Qualitative SAMPLE TYPE: Synthetic Whole Blood-like Sample | | |
|---|--|---|
| PROGRAM CODES | FORMAT | COMPATIBILITY |
| SC11018 SC11012 SC11013 | 2 vial; 0.5mL each (1 x POS, 1 x NEG) 2 vial; 0.5mL each (2 x NEG) 2 vial; 0.5mL each (2 x POS) | Rapid Diagnostic Tests (RDTs) testing serum, plasma or capillary whole blood for the target analyte(s). |
| HBsAg anti-HCV anti-HIV anti- <i>Treponema pallidum</i> | | |
| DESCRIPTION | | |
| The positive vial consists of a human whole blood-like sample known to be positive for HBsAg, anti-HCV, anti-HIV and/or anti- <i>Treponema pallidum</i> at a known reactivity. The negative sample is uninfected human whole blood-like sample. | | |

2. MULTI-MARKER SEROLOGY RDT POC EQA

| SHIPPING CONDITION: Ambient ANALYSIS: Qualitative SAMPLE TYPE: Synthetic Whole Blood-like Sample | | |
|---|---------------------------|---|
| PROGRAM CODES | FORMAT | COMPATIBILITY |
| MMSR4 | 4 vial; 0.5mL each | Rapid Diagnostic Tests (RDTs) testing serum, plasma or capillary whole blood for the target analyte(s). |
| HBsAg anti-HCV anti-HIV anti- <i>Treponema pallidum</i> | | |
| DESCRIPTION | | |
| Each vial consists of human whole blood-like sample, positive or negative for HBsAg, anti-HIV, anti-HCV and/or anti- <i>Treponema pallidum</i> of various concentrations. | | |

C. trachomatis, N. gonorrhoeae



1. C. TRACHOMATIS & N. GONORRHOEAE SWAB MOLECULAR COMPETENCY

| SHIPPING CONDITION: Ambient ANALYSIS: Qualitative SAMPLE TYPE: Clinical Swab | | |
|---|--|--|
| PROGRAM CODES | FORMAT | COMPATIBILITY |
| MC17098 MC17092 MC17093 | 2 dried swabs (1 x POS, 1 x NEG) 2 dried swabs (2 x NEG) 2 dried swabs (2 x POS) | No known compatibility issues with any molecular method or analyser. |
| C. trachomatis N. gonorrhoeae | | |
| DESCRIPTION | | |
| The positive dried swab contains clinical material known to be positive for C. trachomatis and/or N. gonorrhoeae. The negative dried swab contains uninoculated buffer. | | |

2. C. TRACHOMATIS & N. GONORRHOEAE SWAB MOLECULAR POC EQA

| SHIPPING CONDITION: Ambient ANALYSIS: Qualitative SAMPLE TYPE: Clinical Swab | | |
|---|-------------|--|
| PROGRAM CODES | FORMAT | COMPATIBILITY |
| CNTR4 | 4 dry swabs | No known compatibility issues with any molecular method or analyser. |
| C. trachomatis N. gonorrhoeae | | |
| DESCRIPTION | | |
| Each swab contains different concentrations of clinical materials known to be positive for C. trachomatis and/or N. gonorrhoeae. Swabs may be infected with various serovars of Chlamydia or Neisseria spp. | | |

1. SYPHILIS SEROLOGY RDT COMPETENCY

| SHIPPING CONDITION: Ambient ANALYSIS: Qualitative SAMPLE TYPE: Synthetic Whole Blood-like Sample | | |
|--|--|--|
| PROGRAM CODES | FORMAT | COMPATIBILITY |
| SC17068 SC17062 SC17063 | 2 vial; 0.5mL each (1 x POS, 1 x NEG) 2 vial; 0.5mL each (2 x NEG) 2 vial; 0.5mL each (2 x POS) | Syphilis Rapid Diagnostic Tests (RDTs) testing serum, plasma or capillary whole blood. |
| anti- <i>Treponema pallidum</i> | | |
| DESCRIPTION | | |
| The positive vial consists of a human whole blood-like sample known to be positive for anti- <i>Treponema pallidum</i> at a known reactivity. The negative sample is uninfected human whole blood-like sample. | | |

2. SYPHILIS SEROLOGY RDT POC EQA

| SHIPPING CONDITION: Ambient ANALYSIS: Qualitative SAMPLE TYPE: Synthetic Whole Blood-like Sample | | |
|--|---------------------------|--|
| PROGRAM CODES | FORMAT | COMPATIBILITY |
| TPSR4 | 4 vial; 0.5mL each | Syphilis Rapid Diagnostic Tests (RDTs) testing serum, plasma or capillary whole blood. |
| anti- <i>Treponema pallidum</i> | | |
| DESCRIPTION | | |
| Each vial consists of human whole blood-like sample, positive or negative for anti- <i>Treponema pallidum</i> of various concentrations. | | |

1. TUBERCULOSIS MOLECULAR COMPETENCY

| SHIPPING CONDITION: Ambient ANALYSIS: Qualitative SAMPLE TYPE: Clinical Liquid Sample | | |
|--|---|--|
| PROGRAM CODES | FORMAT | COMPATIBILITY |
| MC18118 MC18112 MC18113 | 2 vial; 1.2mL each (1 x POS, 1 x NEG) 2 vial; 1.2mL each (2 x NEG) 2 vial; 1.2mL each (2 x POS) | No known compatibility issues with any method or analyser. |
| <i>M. tuberculosis</i> Complex bacteria | | |
| DESCRIPTION | | |
| The positive vial consists of inactivated <i>M. tuberculosis</i> bacteria suspended in a buffer. The negative vial contains uninoculated buffer. | | |

2. TUBERCULOSIS MOLECULAR POC EQA

| SHIPPING CONDITION: Ambient ANALYSIS: Qualitative SAMPLE TYPE: Clinical Liquid Sample | | |
|---|--------------------|--|
| PROGRAM CODES | FORMAT | COMPATIBILITY |
| MTBR4 | 4 vial; 1.2mL each | No known compatibility issues with any method or analyser. |
| <i>M. tuberculosis</i> and drug resistant strains | | |
| DESCRIPTION | | |
| Each vial contains either uninoculated buffer or inactivated <i>M. tuberculosis</i> bacteria at different concentrations. | | |



IN-DEVELOPMENT

HPV & Group A Strep



The following programs are currently in-development and not yet available for enrolment:

- 1. HPV Molecular**
- 2. Group A Strep Molecular**

If you are interested in any of these upcoming programs or would like to discuss your laboratory's needs, please get in touch today.



+61 3 9418 1111



info@nrlquality.org.au



nrlquality.org.au

